Association for Behavior Analysis International

The Association for Behavior Analysis International® (ABAI) is a nonprofit membership organization with the mission to contribute to the well-being of society by developing, enhancing, and supporting the growth and vitality of the science of behavior analysis through research, education, and practice.


36th Annual Convention; San Antonio, TX; 2010

Event Details

Previous Page


Invited Paper Session #40
How Behavior Analysts Can Impact the Use of Psychotropic Medication for Challenging Behavior
Saturday, May 29, 2010
2:00 PM–2:50 PM
103AB (CC)
Area: DDA; Domain: Applied Behavior Analysis
Chair: Joel Eric Ringdahl (University of Iowa)
JENNIFER R. ZARCONE (University of Rochester Medical Center)
Jennifer Zarcone obtained her PhD from the Behavior Analysis program at the University of Florida, Department of Psychology in 1993. She is currently the Director of the Community Consultation Program in the Department of Pediatrics, University of Rochester Medical Center. The program has 11 faculty members who conduct research and provide expertise to local schools and agencies for students with autism and other behavior challenges. She is a Board Certified Behavior Analyst and a licensed psychologist in New York State. She has served for the past three years on the Executive Committee for the Association for Positive Behavior Support, most recently as President. She is a Member-at-Large on the Board of Directors for New York State Association for Behavior Analysis and is currently an Associate Editor for the Journal of Applied Behavior Analysis. Her areas of expertise are in autism, severe behavior disorders, clinical trials of medications, and Prader-Willi syndrome.
Abstract: The focus of this presentation is on how behavior analysts can play a role when psychotropic medication has been prescribed to treat significant behavior problems. Specifically, the ideal guidelines for conducting clinical trial research will be discussed and how these guidelines can be adapted to nonresearch settings (e.g., schools, home, residential facilities) with individuals with intellectual disabilities. The focus of the presentation will be on the most commonly used behavioral measures, including rating scales, direct observation, and functional analysis measures and how they can be used within the context of medication trials. Data will be presented from each of these types of measures. Finally, the need for measures of social validity and consumer satisfaction as well as collaboration across disciplines will be discussed.



Back to Top
Modifed by Eddie Soh